Cellectis (NASDAQ:CLLS) Stock Crosses Above 50 Day Moving Average – What’s Next?

Shares of Cellectis S.A. (NASDAQ:CLLS) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.97 and traded as high as $3.60. Cellectis shares last traded at $3.56, with a volume of 10,170 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Barclays began coverage on shares of Cellectis in a research report on Thursday, May 28th. They set an “overweight” rating and a $9.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cellectis currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Cellectis Stock Down 4.5%

The company has a market cap of $341.16 million, a PE ratio of -5.23 and a beta of 2.91. The business has a 50-day simple moving average of $2.98 and a 200-day simple moving average of $3.40. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. The firm had revenue of $6.90 million for the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after purchasing an additional 3,284,409 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Cellectis during the fourth quarter worth $15,385,000. Citadel Advisors LLC acquired a new position in Cellectis during the third quarter worth $633,000. Marshall Wace LLP grew its holdings in Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.